| HOME >> BIOLOGY >> TECHNOLOGY |
- Company Establishes U.S. subsidiary in Philadelphia Area -
PHILADELPHIA, Feb. 13 /PRNewswire/ -- Cellvizio Inc., a leader in in vivo cellular imaging, announced today the appointment of Chris Tihansky as its President. Cellvizio Inc. is the U.S. subsidiary of Paris-based Mauna Kea Technologies and develops and markets Cellvizio(R), a fundamentally new endoscopic imaging approach which improves patient care by eliminating the need for unnecessary biopsies and enhances the diagnosis of a broad range of diseases via in vivo cellular imaging.
(Photo: http://www.newscom.com/cgi-bin/prnh/20080213/NYW021 )
The appointment coincides with the company establishing its U.S. operations base in the Philadelphia area.
"Cellvizio is increasing its commercialization efforts in the U.S., and Chris is a great fit for leading this," said Sacha Loiseau, Ph.D., founder, president and chief executive officer of Mauna Kea. "He has a unique combination of expertise in the medical technology field, including general management, business development, sales, and product development."
"Cellvizio is an excellent example of a company that has successfully taken a cutting-edge technology from bench top to bedside," explained Chris. "I am very pleased to be leading our team in the U.S. It is our intention to make Cellvizio a standard of care so that as many patients as possible have access to the advantages this technology offers."
"The Philadelphia area is a perfect location for us to rapidly build our business," Chris stated. "It offers ready access to our customer base and a strong talent pool. Additionally, it is increasingly evident that Southeastern Pennsylvania offers a well-developed support infrastructure for emerging med- tech companies."
Chris has 20 years of experience in the emerging medical technology and
healthcare financials services industri
'/>"/>
| SOURCE Cellvizio Inc. Copyright©2008 PR Newswire. All rights reserved |